Skip to main content
Top
Published in: Infection 4/2015

01-08-2015 | Images in Infection

Primary skin melioidosis in a returning traveler

Authors: Kristina Huber, Bryan Thoma, Thomas Löscher, Andreas Wieser

Published in: Infection | Issue 4/2015

Login to get access

Excerpt

A 28-year-old previously healthy female Thai native German resident reported a history of headache and fever with a singular wound for 5 weeks on the lower back after vacation in Bangkok/Thailand. The lesion was elevated with a cauliflower-like aspect (Fig. 1a). The patient reported local tenderness and denied night sweats or weight loss. The physical examination was otherwise unrevealing. Wound-swab cultures were obtained and empirical treatment started with ciprofloxacin 500 mg BID. Blood tests (CBC, CRP, ESR, basic liver- and retention parameters) were within normal limits. Serologically, no evidence for syphilis, Leishmania spp. or HIV. Swab cultures grew whitish wrinkled colonies on blood media which were identified with MALDI-TOF–MS1 [1] to be Burkholderia pseudomallei. AST2 demonstrated susceptibility against tetracycline, piperacillin and quinolones as well as ceftazidime. Resistance against cotrimoxazole, a possible treatment option was detected. Although the wound showed healing tendencies (Fig. 1b) after 7 days of ciprofloxacin treatment, regimen was changed to ceftazidime i.v. 40 mg/kg for 10 days and a follow up of 56 days of doxycycline 100mg BID. The skin closed completely and left a hyperpigmented scar (Fig. 1c). Immuno-Blot against B. pseudomallei LPS-Type-A was positive [2].
Footnotes
1
MALDI-TOF-MS: matrix assisted laser desorption/ionization time of flight mass spectrometry; the system used was the Bruker Microflex/Biotyper package with the regular and bioterror database.
 
2
AST: Antibiotic susceptibility testing; performed according to EUCAST guidelines.
 
Literature
1.
go back to reference Wieser A, et al. MALDI-TOF MS in microbiological diagnostics-identification of microorganisms and beyond (mini review). Appl Microbiol Biotechnol. 2012;93:965–74.PubMedCrossRef Wieser A, et al. MALDI-TOF MS in microbiological diagnostics-identification of microorganisms and beyond (mini review). Appl Microbiol Biotechnol. 2012;93:965–74.PubMedCrossRef
2.
go back to reference Tuanyok A, et al. The genetic and molecular basis of O-antigenic diversity in Burkholderia pseudomallei lipopolysaccharide. PLoS Negl Trop Dis. 2012;6:e1453.PubMedCentralPubMedCrossRef Tuanyok A, et al. The genetic and molecular basis of O-antigenic diversity in Burkholderia pseudomallei lipopolysaccharide. PLoS Negl Trop Dis. 2012;6:e1453.PubMedCentralPubMedCrossRef
3.
go back to reference Frangoulidis D, et al. ‘Imported’ melioidosis in Germany: relapse after 10 years. Trans R Soc Trop Med Hyg. 2008;102:S40–1.PubMedCrossRef Frangoulidis D, et al. ‘Imported’ melioidosis in Germany: relapse after 10 years. Trans R Soc Trop Med Hyg. 2008;102:S40–1.PubMedCrossRef
5.
go back to reference Gibney KB, et al. Cutaneous melioidosis in the tropical top end of Australia: a prospective study and review of the literature. Clin Infect Dis. 2008;47:603–9.PubMedCrossRef Gibney KB, et al. Cutaneous melioidosis in the tropical top end of Australia: a prospective study and review of the literature. Clin Infect Dis. 2008;47:603–9.PubMedCrossRef
Metadata
Title
Primary skin melioidosis in a returning traveler
Authors
Kristina Huber
Bryan Thoma
Thomas Löscher
Andreas Wieser
Publication date
01-08-2015
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 4/2015
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-015-0735-4

Other articles of this Issue 4/2015

Infection 4/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.